Physician profile
John P Gardner
NPI 1124088620
$2,739.15
in general payments reported to CMS, 2019-2025
24 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $138 · 2021: $312 · 2022: $537 · 2023: $364 · 2024: $629 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $516.97 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $385.14 | 2019-2025 | |
| Amgen INC. | $340.46 | 2020-2025 | Repatha, Otezla, Evenity |
| Inari Medical, INC. | $173.79 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Bayer Healthcare Pharmaceuticals INC. | $154.69 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $151.18 | 2021-2024 | Breztri, Nexium, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.99 | 2021-2025 | Xifaxan |
| Novo Nordisk INC | $141.16 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $132.89 | 2019-2025 | |
| Glaxosmithkline, LLC. | $93.60 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $85.54 | 2022-2023 | Xarelto |
| Astellas Pharma US INC | $74.90 | 2024-2025 | Veozah |
| Philips North America LLC | $62.09 | 2024 | (Cm9) Amb Mon & Diag Und |
| Exact Sciences Corporation | $53.92 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $34.92 | 2022-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $32.79 | 2021-2024 | Intellis Adaptivestim |
| Allergan, INC. | $26.84 | 2019 | |
| Sanofi-Aventis U.S. LLC | $25.70 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $22.53 | 2025 | Eliquis |
| Idorsia Pharmaceuticals US INC | $18.43 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $17.50 | 2023 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $17.23 | 2025 | Trintellix |
| Abbott Laboratories | $15.29 | 2021 | |
| Eisai INC. | $12.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.